Bayer Wins Ruling Upholding Verdict Over Takeda Hemophilia Drug

An appeals court Monday upheld a 2019 jury verdict that the Adynovate hemophilia drug made by Takeda’s Baxalta and Nektar Therapeutics infringed a Bayer patents for recombinant forms of human factor VIII.

• The jury awarded $155 million in damages; the final total was $181.8 million after the judge added interest and royalties on additional sales of the drug
• There is “substantial evidence to support the jury’s finding” of infringement and damages, the U.S. Court of Appeals for the Federal Circuit ruled
• Baxalta also challenged the validity findings and the judge’s decision to add supplemental damages, while Bayer appealed the ...